HAEGARDA is an injectable medicine used to prevent swelling and/or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE).

In a clinical study, 40% of people on 60 IU/kg were attack free during the 16-week treatment period. In a long-term follow up study, similar responses were seen up to a maximum of 2.5 years.

Proven C1-INH Efficacy & Established Safety Profile

HAEGARDA safely and effectively normalizes the system with C1–INH for proven long-term attack prevention²

Family Planning

The World Allergy Organization suggests C1–INH as first‑line long-term prophylaxis therapy during pregnancy³

Pediatrics

Proven efficacy & established safety profile in pediatrics 6+

EXPLORE EFFICACY

number one prescribed c1-inh replacement

Get your appropriate patients started on HAEGARDA

DOWNLOAD THE REFERRAL & QUICKSTART FORM

References: 1. Craig T, Feuersenger H, Pragst I, et al. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202-208. 2. Data on File. Available from CSL Behring as DOF HGD-011. 3. Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities. World Allergy Organ J. 2026;19(4):101335. doi:10.1016/j.waojou.2026.101335. 4. Data on File. Available from CSL Behring as DOF HGD-002.